Skip to main content

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

David Tabernero Caellas

Institutions of which they are part

Senior researcher
Liver Diseases
Vall Hebron Institut de Recerca

Projects

Complejidad de la cuasiespecie del virus de la Hepatitis B en las regiones X, precore y core: Asociación con la severidad de la infección

IP: -
Collaborators: Clara Ramírez Serra, Lluis Castells Fusté, Silvia Camòs Anguila, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 98373
Reference: PI12/01893
Duration: 01/01/2013 - 31/03/2016

Prevalencia de las quasispecies mutantes en antígeno de superficie en paceintes con hepatitis crónica B y trasplantados por hepatitis B

IP: Maria Buti Ferret
Collaborators: Andrea Caballero Garralda, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 275715.44
Reference: PI11/01973
Duration: 01/01/2012 - 28/02/2015

Análisis de la cuasispecie viral en la infección por virus de la hepatitis B: evolución natural yu asociada al tratamiento antiviral

IP: -
Collaborators: Maria Buti Ferret, David Tabernero Caellas
Funding agency: Instituto de Salud Carlos III
Funding: 90750
Reference: PI09/00899
Duration: 01/01/2010 - 31/12/2012

Unitat de Recerca en Malalties Hepatobiliars

IP: Joan Genescà Ferrer
Collaborators: Immaculada Raurell Saborit, Antonio González Fernández, Lluis Castells Fusté, Silvia Sauleda Oliveras, Lluís Palenzuela Díaz, Maria Buti Ferret, Josep Quer Sivila, Maria Nieves Martell Pérez-Alcalde, Juan Ignacio Esteban Mur, David Tabernero Caellas
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 54080
Reference: 2009 SGR 383
Duration: 01/01/2010 - 30/04/2014

Related news

Using computed tomography (CT), with or without contrast, it is possible to perform an accurate and safe detection of the disease without the need for biopsies and avoiding the limitations of other non-invasive diagnostic tools.

On World Clinical Trials Day, we highlight some of the studies we have participated in that confirm the efficacy of new drugs, allowing their approval by regulatory agencies.

Preliminary study results confirm that the drug resmetirom reduces the presence of fat, inflammation, cell damage and fibrosis in the liver.

Related professionals

Julia Basallote Garcia deQuiros

Julia Basallote Garcia deQuiros

Tècnic/a Grau Superior
National Unit
Competitive Research Directorate
Read more
Riccardo Tiberi Antonio

Riccardo Tiberi Antonio

Research technician
Stroke research
Read more
Gino Freddy Sena Ganse

Gino Freddy Sena Ganse

Predoctoral researcher
Cardiovascular Diseases
Read more
Laura Martinez Cantero

Laura Martinez Cantero

Fundraising Unit
Communication Directorate
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.